Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of$3.96 per share was 1.2% above analysts’ consensus estimates. Is now the time to buy BDX? Find out in our full research report (it’s free for active Edge members). BD (BDX) Q3 CY2025 Highlights: Revenue: $5.89 billion vs analyst estimates of$5.91 billion (8.3% year-on-year growth, in line) Adjusted EPS: $3.96 v ...